Navigation Links
Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma

cular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. There have been rare reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome in patients receiving VELCADE. Some of these events have been fatal. A higher proportion of these events have been reported in Japan. There have been rare reports of RPLS in patients receiving VELCADE. RPLS is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. VELCADE is associated with thrombocytopenia and neutropenia. There have been reports of gastrointestinal and intracerebral hemorrhage in association with VELCADE. Transfusions may be considered. Complete blood counts (CBC) should be frequently monitored during treatment with VELCADE. Rare cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions.

Safety Data: In 1163 patients in multiple myeloma and mantle cell lymphoma studies, the most commonly reported adverse events were asthenic conditions (64%), nausea (55%) in single-agent VELCADE, diarrhea (52%), constipation (41%), peripheral neuropathy (39%), thrombocytopenia (36%), appetite decrease, including reports of anorexia (36%), pyrexia (34%), vomiting (33%) and anemia (29%). Twenty percent of patients reported at least one episode of grade 4 toxicity; the most common grade 4 toxicities were thrombocytopenia (5%) and neutropenia (3%). Fifty percent of patients reported serious adverse events. The most commonly reported serious adverse events were pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%).

For more informa
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
3. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
4. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
10. Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
Post Your Comments:
(Date:4/17/2015)... 17, 2015 Today, the Pharmaceutical Research ... from 12 biopharmaceutical companies as "We Work For ... advocacy and community service. Established in ... were created by the biopharmaceutical industry to honor ... careers, but have also shown an outstanding commitment ...
(Date:4/17/2015)... Va. , April 17, 2015   ... distribution of radiopharmaceuticals, announced today that it has signed ... Molecular North America, Inc. (IBAM NA), to Illinois Health and ... to operate as an independent company headquartered in ... positioned to take advantage of new product and footprint ...
(Date:4/17/2015)... Research and Markets ( http://www.researchandmarkets.com/research/256szd/corporate ) ... of Pharma in 2014 - a Perspective of Mental ... their offering. For the first time, in ... reputation of the pharmaceutical industry held by patient groups ... of patient organisations representing all therapy areas. ...
Breaking Medicine Technology:PhRMA Applauds 2015 We Work For Health Champion Award Winners 2PhRMA Applauds 2015 We Work For Health Champion Award Winners 3Health Care System to Acquire IBA Molecular North America 2Health Care System to Acquire IBA Molecular North America 3Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 2Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 3
... and TORONTO, Sept. 7, 2011 Generex Biotechnology ... that Mark Fletcher, the Company,s President & Chief ... of the Company,s wholly-owned subsidiary, Antigen Express, Inc. ... at  the Rodman & Renshaw 13th Annual Healthcare ...
... YORK, Sept. 7, 2011 ACCESS PHARMACEUTICALS, ... a biopharmaceutical company leveraging its proprietary drug-delivery platforms to ... and diabetes, announced that it has contracted with CuraScript, ... expand its specialty pharmacy and third party logistics networks ...
Cached Medicine Technology:Generex to Present at the Rodman & Renshaw 13th Annual Healthcare Conference 2Generex to Present at the Rodman & Renshaw 13th Annual Healthcare Conference 3Access Pharmaceuticals and CuraScript Team Up to Further Expand MuGard Market Access and Distribution 2Access Pharmaceuticals and CuraScript Team Up to Further Expand MuGard Market Access and Distribution 3Access Pharmaceuticals and CuraScript Team Up to Further Expand MuGard Market Access and Distribution 4
(Date:4/17/2015)... April 17, 2015 “We have seen healing, ... the past and present,” said Chaplain Shawn Kafader of Friendship ... felt like they had anything to contribute have created beautiful ... overseen a new art therapy program that was launched to ... Masters student from School of the Art Institute in Chicago, ...
(Date:4/17/2015)... In Defense of Christians (IDC) Executive Director ... April 15th, the European Parliament joined its voice with ... Armenian Genocide, “paying tribute, on the eve of the ... Armenian victims who perished in the Ottoman Empire.” ... this timely and needed recognition of a tragic episode ...
(Date:4/17/2015)... DC (PRWEB) April 17, 2015 Representatives ... HHT Diagnoses and Treatment Act HR 1849 in congress ... diagnosis rates and treatment for patients with the genetic ... in the past, would be the first to create ... and appropriate treatment of hereditary hemorrhagic telangiectasia. This would ...
(Date:4/17/2015)... Hills, California (PRWEB) April 17, 2015 ... stands above in his new offering of platelet-rich plasma ... Orthopedic Sports Medicine (MOSM) is known for its ... Dr. Meier brings extensive surgical experience lacking in many ... and stem cell treatments are utilized for pain management ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Most dental ... dental restoration units are made overseas by foreign dental ... domestic labs remain unregulated in more than 40 states ... National Association of Dental Laboratories has created ... raise awareness among patients about the consequences that could ...
Breaking Medicine News(10 mins):Health News:Healing At Friendship Village Due To Art Therapy 2Health News:In Defense of Christians Condemns Armenian Genocide 2Health News:In Defense of Christians Condemns Armenian Genocide 3Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3Health News:National Association Urges Transparency in Dental Industry 2
... TORONTO, Nov. 12 /PRNewswire-FirstCall/ - Transition Therapeutics Inc.,("Transition" or ... hold a,conference call on Wednesday, November 14, 2007 at ... financial results. Dr. Tony Cruz, Chairman,and Chief Executive Officer ... its financial results for this period in a press ...
... Incorporated,(Nasdaq: VPHM ) today announced that the ... Medicines Agency (EMEA) has granted orphan,drug designation for ... patients with impaired cell-mediated immunity. The EMEA,s,"Orphan Medicinal ... drugs which may provide significant benefit to patients,suffering ...
... spirometry to clinical exams benefits those with symptoms , MONDAY, ... diagnosing and treating the lung illness known as stable ... American College of Physicians (ACP). , COPD, typically caused ... affects more than 5 percent of American adults and is ...
... Now has,selected its $7,500 Grand Prize winner in its ... walks away with the big prize,after a 3-month competition ... will receive $250 in the contest. The winning video ... "Brendan Hayward captured, in just 30 seconds, what ...
... Mich., Nov. 12 Leading health care risk,management ... third,quarter results for the period ended Sept. 30, ... quarter and first nine months of the year. ... medical,professional liability insurance and integrated risk management products,and ...
... Medical,Association (AMA) proudly presented Portland physician Richard Allen, ... its semi-annual,policy-making meeting. Dr. Allen is the first ... for meritorious service in the science and art,of ... advancing medical education," said,AMA President Ron Davis, M.D. ...
Cached Medicine News:Health News:Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2008 Financial Results on Wednesday, November 14, at 8:30 A.M. EST 2Health News:ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM) 2Health News:ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM) 3Health News:ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM) 4Health News:New Guideline Targets Treatment of Stable COPD 2Health News:Psoriasis Cure Now Video Contest $7,500 Grand Prize Winner Announced 2Health News:FinCor Holdings Posts Double-Digit Increases in Revenue and Net Income for Third Quarter 2Health News:FinCor Holdings Posts Double-Digit Increases in Revenue and Net Income for Third Quarter 3Health News:Portland Physician Wins AMA Distinguished Service Award 2
... The PipetBoy Pipettor is light as a feather ... aspiration speed can be continuously adjusted. The pipette ... be autoclaved. Two dosing knobs enable fine dosing ... plastic an/or glass pipettes from 0.1 to 100 ...
Precise, safe, and fatigue-free series pipetting using graduated pip...
Inquire...
Inquire...
Medicine Products: